Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 5:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,506 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus Complication Clear all
Completed No phase listed Observational Accepts healthy volunteers

Prognostic Indicators as Provided by the EPIC ClearView

NCT01476995
View directory record Official record
Conditions
Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation, Hypertension, Pyelonephritis, Acute Renal Failure, Renal Failure, Viral Hepatitis, Alcoholic Hepatitis, Steatohepatitis, Cirrhosis, Asthma, COPD, Bronchitis, Emphysema, Pneumonia, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Diverticulitis, Peptic Ulcer Disease, Irritable Bowel Syndrome, Cholecystitis, Pancreatitis, Malabsorption Disorders, Celiac Sprue, Diabetes
Interventions
Not listed
Lead sponsor
Epic Research & Diagnostics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Oct 12, 2026, 5:22 PM EDT
Withdrawn No phase listed Observational

Protocol to Validate the Performance of the Mellitus Glycated CD59 ELISA for Gestational Diabetes Screening

NCT03865901
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Mellitus GCD59 Test
Diagnostic Test
Lead sponsor
Mellitus, LLC
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
19
States / cities
Birmingham, Alabama • Orange, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 12, 2026, 5:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Weight Changes During and After Pregnancy in Women With Gestational Diabetes

NCT02388958
View directory record Official record
Conditions
Gestational Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older · Female only
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 12, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Results available

A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)

NCT00643760
View directory record Official record
Conditions
Neuropathy, Diabetic
Interventions
Placebo, GEn 1200mg/day, GEn 2400mg/day, GEn 3600mg/day, Pregabalin
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
90
States / cities
Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 81 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Oct 12, 2026, 5:22 PM EDT
Completed Not applicable Interventional

Evaluating The Efficacy Of A Keratin Graft In Treating Non-Healing Diabetic Foot Ulcers

NCT05797285
View directory record Official record
Conditions
Ulcer Healing, Diabetic Foot Ulcer
Interventions
human keratin graft
Device
Lead sponsor
ProgenaCare Global, LLC
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Miami, Florida • Frederick, Maryland • Salem, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 12, 2026, 5:22 PM EDT
Completed Not applicable Interventional

Diabetes Group Prenatal Care

NCT02444325
View directory record Official record
Conditions
Pregnancy, Gestational Diabetes, Type 2 Diabetes
Interventions
Group prenatal care
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Denver, Colorado • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Oct 12, 2026, 5:22 PM EDT
Terminated Not applicable Interventional Results available

SD-OCT Angiography

NCT02510885
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
AngioVue SD-OCT
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 12, 2026, 5:22 PM EDT
Terminated Early Phase 1 Interventional

Glyburide vs Glucovance in the Treatment of GDM

NCT02726490
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Glyburide, Glucovance
Drug
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Oct 12, 2026, 5:22 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

NCT01621178
View directory record Official record
Conditions
Type 2 Diabetes, Chronic Kidney Disease
Interventions
Dulaglutide, Insulin glargine, Insulin lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
47
States / cities
Montgomery, Alabama • Azusa, California • Granada Hills, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 12, 2026, 5:22 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Intraoperative OCT Guidance of Intraocular Surgery II

NCT03713268
View directory record Official record
Conditions
Macular Holes, Epiretinal Membrane, Diabetic Retinopathy, Retinal Detachment, Retinal Disease, Preretinal Fibrosis, Cataract, Ocular Tumor, Strabismus, Healthy
Interventions
Microscope integrated optical coherence tomography
Device
Lead sponsor
Duke University
Other
Eligibility
4 Weeks and older
Enrollment
262 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 12, 2026, 5:22 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

NCT02547935
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, CKD and Albuminuria
Interventions
Dapagliflozin 10 mg, Saxagliptin 2.5 mg, Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
37
States / cities
Peoria, Arizona • Chula Vista, California • Concord, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 12, 2026, 5:22 PM EDT
Completed No phase listed Observational

A Real World Data Collection of Human Amniotic Membrane(s) on Diabetic Foot Ulcers, Venous Leg Ulcers, Pressure Ulcers and Post Operative Wounds

NCT07078968
View directory record Official record
Conditions
Venous Leg Ulcer (VLU), Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Interventions
Tri-Membrane Wrap™, Membrane Wrap™, Membrane Wrap-Hydro™, Standard of Care
Device · Other
Lead sponsor
BioLab Holdings
Industry
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
4
States / cities
Phoenix, Arizona • Toms River, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 12, 2026, 5:22 PM EDT
Terminated No phase listed Observational

3C Patch® Medicare Claims Study

NCT03997526
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
3C Patch
Device
Lead sponsor
Reapplix
Other
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Phoenix, Arizona • Natchitoches, Louisiana • Opelousas, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 12, 2026, 5:22 PM EDT
Active, not recruiting No phase listed Observational

Prospective Decision Impact Clinical Utility Trial of KidneyIntelX

NCT05198284
View directory record Official record
Conditions
Diabetic Kidney Disease, Chronic Kidney Diseases, Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3
Interventions
KidneyIntelX
Diagnostic Test
Lead sponsor
Renalytix AI, Inc.
Industry
Eligibility
23 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 12, 2026, 5:22 PM EDT
Completed Not applicable Interventional

Trial of Dehydrated Human Amnion/Chorion Membrane (dHACM) In the Management of Diabetic Foot Ulcers

NCT01693133
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Standard of Care: Moist Wound Therapy and Offloading, EpiFix plus Standard of Care
Other
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
20
States / cities
Birmingham, Alabama • Bakersfield, California • Castro Valley, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Oct 12, 2026, 5:22 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of Artacent™ for Treatment Resistant Lower Extremity Venous and Diabetic Ulcers

NCT02838784
View directory record Official record
Conditions
Venous Ulcer, Foot Ulcer, Diabetic
Interventions
Artacent Human Amniotic Membrane, Standard of Care
Other · Procedure
Lead sponsor
Tides Medical
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
7
States / cities
Arcadia, California • New Iberia, Louisiana • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 12, 2026, 5:22 PM EDT
Withdrawn Phase 3 Interventional

Empaglifozin in Early Diabetic Kidney Disease

NCT03173963
View directory record Official record
Conditions
Diabetic Kidney Disease, Diabetes Mellitus Type 2
Interventions
Empagliflozin, Placebo
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 12, 2026, 5:22 PM EDT
Completed Phase 1 Interventional

Effect of Renal Impairment on the Pharmacokinetics of NN9535

NCT00833716
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2, Renal Impairment
Interventions
semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 12, 2026, 5:22 PM EDT
Terminated Phase 2 Interventional Results available

The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes

NCT02915263
View directory record Official record
Conditions
Diabetes Complications, Diabetes Mellitus, Diabetic Neuropathies
Interventions
IGIV-C, 0.9% Sodium Chloride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 12, 2026, 5:22 PM EDT
Completed Phase 3 Interventional Results available

Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)

NCT00032487
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin, Glimepiride, Rosiglitazone, Metformin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
1,791 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 12, 2026, 5:22 PM EDT
Completed Phase 1 Interventional

Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Diabetic Foot Ulcers

NCT02652754
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Granexin® gel
Drug
Lead sponsor
Xequel Bio, Inc.
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Augusta, Georgia • Spartanburg, South Carolina • Salem, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 12, 2026, 5:22 PM EDT
Terminated Phase 3 Interventional Results available

A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)

NCT01063868
View directory record Official record
Conditions
Diabetic Neuropathy, Painful, Diabetic Polyneuropathy
Interventions
Tapentadol extended release (ER), Oxycodone controlled release (CR)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
23
States / cities
Mesa, Arizona • Tucson, Arizona • Fruitland Park, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 12, 2026, 5:22 PM EDT
Recruiting No phase listed Observational

A Long-Term Follow-Up Study of Participants Exposed to REACT

NCT05918523
View directory record Official record
Conditions
Diabetic Kidney Disease, Chronic Kidney Diseases
Interventions
Renal Autologous Cell Therapy (REACT)
Biological
Lead sponsor
Prokidney
Industry
Eligibility
30 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Meridian, Idaho
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 12, 2026, 5:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function

NCT03618420
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Nephropathy, Diabetic Nephropathies, Juvenile Diabetes, Diabetes Mellitus Complication, Autoimmune Diabetes, Type 1 Diabetes Mellitus
Interventions
Aminohippurate Sodium Inj 20%, Iohexol Inj 300 mg/mL
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 12, 2026, 5:22 PM EDT